Clinical Trial Update: DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of DRP-104 in patients with NFE2L2/KEAP1-altered non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DRP-104

Snippet

Sponsor: NYU Langone Health | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: RECRUITING